CTNM vs GNRC · $429.6M cap vs P/E 82, rev $1.17B
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) versus Generac Holdings Inc (GNRC) — a side-by-side from cached financials, not a winner call.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
Generac Holdings Inc (GNRC) is a specialty industrial machinery company listed on US.
Latest reported CTNM revenue for 2024-09-30 was $0. Net income was -$27.7M. CTNM currently screens at market cap $429.6M.
Latest reported GNRC revenue for 2026-06-30 was $1.17B. Net income was $143.2M. Revenue was up 10.8% from 2026-03-31 to 2026-06-30. GNRC currently screens at market cap $15.40B and trailing P/E 82.0.
CTNM currently screens at market cap $429.6M. GNRC currently screens at market cap $15.40B and trailing P/E 82.0.
Not investment advice. Open the CTNM and GNRC stock pages for the full models.
Not investment advice.